Back to Report Store Home

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

  • Published: Dec-2015
  • Report Code: GBIHC377MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Pancreatic Cancer Therapeutics, Five-Year Survival by Age 19

Figure 2: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters – Marketed Products, Adjuvant Therapies Post-Disease Resection 33

Figure 3: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters – Marketed Products, First-Line Treatment Unresectable Disease 34

Figure 4: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters – Marketed Products, Second-Line Treatment Unresectable Disease 35

Figure 5: Pancreatic Cancer Therapeutics, Global, Pipeline by Stage of Development, Molecule Type and Program Type 38

Figure 6: Pancreatic Cancer Therapeutics, Global, Pipeline by Mechanism of Action, 2015 41

Figure 7: Pancreatic Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2015 42

Figure 8: Pancreatic Cancer Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2015 43

Figure 9: Pancreatic Cancer Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006–2015 44

Figure 10: Pancreatic Cancer Therapeutics, Global, Clinical Trial Failure Rate by Mechanism of Action, 2006–2015 45

Figure 11: Pancreatic Cancer Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006–2015 47

Figure 12: Pancreatic Cancer Therapeutics, Global, Clinical Trial Duration by Phase and Mechanism of Action, 2006–2015 49

Figure 13: Pancreatic Cancer Therapeutics, Global, Clinical Trial Size by Molecule Type, 2006–2015 51

Figure 14: Pancreatic Cancer Therapeutics, Global, Clinical Trial Size by Mechanism of Action, 2006–2015 52

Figure 15: Pancreatic Cancer Therapeutics, Global, Cumulative Clinical Trial Size by Molecule Type, 2006–2015 53

Figure 16: Pancreatic Cancer Therapeutics, Global, Cumulative Clinical Trial Size by Mechanism of Action, 2006–2015 54

Figure 17: Pancreatic Cancer Therapeutics, Global, Estimated Sales of TH-302 ($m), 2019–2021 58

Figure 18: Pancreatic Cancer Therapeutics, Global, Estimated Sales of Ruxolitinib Phosphate ($m), 2018–2021 61

Figure 19: Pancreatic Cancer Therapeutics, Global, Estimated Sales of HyperAcute Pancreas ($m), 2019–2021 63

Figure 20: Pancreatic Cancer Therapeutics, Global, Estimated Sales of G17DT ($m), 2018–2021 65

Figure 21: Pancreatic Cancer Therapeutics, Global, Estimated Sales of Clivatuzumab Tetraxetan ($m), 2019–2021 68

Figure 22: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters – Pipeline and Marketed Products (Light Blue), Adjuvant Therapies Post-Disease Resection 69

Figure 23: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters – Pipeline and Marketed Products (Light Blue), First-Line Treatment of Unresectable Disease 70

Figure 24: Pancreatic Cancer Therapeutics, Efficacy and Safety Results for Key Parameters – Pipeline and Marketed Products (Light Blue), Second-Line Treatment of Unresectable Disease 71

Figure 25: Pancreatic Cancer Therapeutics, Product Competitiveness Framework in Metastatic Disease 71

Figure 26: Pancreatic Cancer Therapeutics Market, Global, Treatment Usage Patterns (‘000 patients) and Market Revenues ($m), 2014–2021 74

Figure 27: Pancreatic Cancer Therapeutics, US, Treatment Usage Patterns (‘000 patients) and Annual Cost of Therapy ($), 2014–2021 75

Figure 28: Pancreatic Cancer Therapeutics Market, US, Market Revenues ($m), 2014–2021 77

Figure 29: Pancreatic Cancer Therapeutics, Canada, Treatment Usage Patterns (‘000 patients) and Annual Cost of Therapy ($), 2014–2021 78

Figure 30: Pancreatic Cancer Therapeutics Market, Canada, Market Revenues ($m), 2014–2021 79

Figure 31: Pancreatic Cancer Therapeutics, Top Five European Markets, Treatment Usage Patterns (‘000 patients), 2014–2021 81

Figure 32: Pancreatic Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014–2021 82

Figure 33: Pancreatic Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2014–2021 84

Figure 34: Pancreatic Cancer Therapeutics, Japan, Treatment Usage Patterns (‘000) and Annual Cost of Therapy ($), 2014–2021 85

Figure 35: Pancreatic Cancer Therapeutics, Japan, Market Size ($m), 2014–2021 86

Figure 36: Pancreatic Cancer Therapeutics, Global, Co-Development Deals by Region, Value ($m), Year and by Phase, 2006–2014 92

Figure 37: Pancreatic Cancer Therapeutics, Global, Co-Development Deals by Molecule Type and Mechanism of Action 2006–2014 93

Figure 38: Pancreatic Cancer Therapeutics, Global, Licensing Deals by Region, Value ($m), Year and by Phase, 2006–2014 96

Figure 39: Pancreatic Cancer Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2014 97

Figure 40: GBI Research Market Forecasting Model 137

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards